Author:
Padda Sukhmani K.,Krupitskaya Yelena,Chhatwani Laveena,Fisher George A.,Colevas Alexander D.,San Pedro-Salcedo Melanie,Decker Rodney,Latz Jane E.,Wakelee Heather A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference23 articles.
1. Faul MM, Gillig JR, Jirousek MR et al (2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 13:1857–1859
2. Graff JR, McNulty AM, Hanna KR et al (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462–7469
3. Yoshiji H, Kuriyama S, Ways DK et al (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59:4413–4418
4. Lahn M, McClelland P, Ballard D, Mintze K, Thornton D, Sandusky G (2006) Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer. Histopathology 49:429–431
5. Barr LF, Campbell SE, Baylin SB (1997) Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells. Cell Growth Differ 8:381–392
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献